VTRS — Viatris Inc.

Summary of VTRS Q4 2025 Earnings Call

1. Key Financial Results and Metrics:

• Total Revenues: $14.3 billion for 2025, up approximately 2% from 2024 (excluding the impact of divestitures).
• Q4 Revenues: $3.7 billion, a 1% increase year-over-year (adjusted for divestitures).
• Adjusted EBITDA: $4.2 billion for the year.
• Adjusted EPS: $2.35 per share.
• Free Cash Flow: $2.2 billion (excluding transaction-related costs).
• Capital Return: Over $1 billion returned to shareholders through dividends and share buybacks.

2. Strategic Updates and Business Highlights:

• Pipeline Advancements: Five positive phase 3 readouts and significant regulatory progress on multiple assets.
• Acquisitions: Completed 60 regional transactions, including the acquisition of Aculys Pharma in Japan.
• Cost Optimization: Identified $650 million in gross cost savings over three years, with plans to reinvest up to $250 million to enhance growth.
• Strategic Imperatives: Focus on driving base business growth, fueling innovation, and modernizing operations for sustainable growth.
• Regulatory Milestones: Anticipated launches of EFFEXOR and low-dose estrogen weekly patch in 2026, along with several other product approvals.

3. Forward Guidance and Outlook:

• 2026 Revenue Growth: Expected total revenue growth of approximately 2% and adjusted EBITDA growth, supported by strategic initiatives.
• New Product Revenues: Anticipated contributions of $450 million–$550 million from new products.
• Market Growth Expectations:
  • Developed markets expected to grow by 2%.
  • Emerging markets projected growth of 6%.
  • Greater China expected to grow by 3%.
• Financial Flexibility: Projected robust cash flow in 2026, with over $2.5 billion in cash available for deployment.

4. Bad News, Challenges, or Points of Concern:

• India Facility Issues: A fire at the Nashik facility has temporarily halted operations, expected to resume in April. This incident has been factored into 2026 guidance.
• Gross Margin Pressures: Anticipated modest decline in gross margins due to product mix and losses of exclusivity.
• Regulatory Pricing Challenges in Japan: Ongoing mandatory price decreases and the loss of Amitiza mid-year are expected to impact revenue.
• Competitive Pressures: Facing challenges in North America with competitive impacts affecting certain products.

5. Notable Q&A Insights:

• Long-term Growth Path: Management expressed confidence in achieving mid-single-digit revenue growth over the next few years, driven by base business stability and upcoming product launches.
• Cost Savings Breakdown: Approximately 50% of the $650 million savings will come from headcount reductions, with the remainder from COGS efficiencies.
• India Recovery Assumptions: Less than 1% growth from India recovery is included in the 2026 guidance, with prior year impacts managed through operational adjustments.
• Launch Expectations for Meloxicam: The company aims for a strong launch strategy focused on acute pain management, with a significant emphasis on targeting specific physician groups.

Overall, Viatris Inc. demonstrated solid performance in 2025, with a strategic focus on growth and operational efficiency, while navigating challenges in specific markets and operational setbacks. The outlook for 2026 appears cautiously optimistic, with plans for new product launches and cost savings initiatives.